Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).
Hani M BabikerErkut Hasan BorazanciVivek SubbiahSanjiv AgarwalaAlain Patrick AlgaziJacob SchachterMichael LotemCorinne Maurice-DrorDaniel HendlerShah RahimianHans MindermanCara L HaymakerDaruka MahadevanChantale BernatchezRavi MurthyRolf HultschNadia KaplanGregory WoodheadCharles HennemeyerSrinivas ChunduruPeter M AndersonAdi DiabIgor PuzanovPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Overall, tilsotolimod monotherapy was generally well tolerated and induced rapid, robust alterations in the tumor microenvironment. See related commentary by Punekar and Weber, p. 5007.